Extraction, isolation and identification of terpenophenols for drug standardization in a medicinal plant

问题：First Access Medical计划生产高质量的药用植物提取物，以治疗患有各种健康问题的患者，包括关节炎中的疼痛、炎症和组织丢失。以植物为基础的处方，甚至从药用植物组织中提取的提取物都含有多种药用相关化合物，包括必须提取、分离和鉴定的萜类苯酚，以实现药物标准化，并评估临床应用。 问题的意义：除非能够以精确的剂量提取、分离、鉴定和评估组成萜烯酚的成分，否则很难将药物活性归因于治疗特定疾病的特定化合物和生产有用的生物药物。因此，迫切需要建立从植物组织和提取物中提取和分离萜类酚化合物的标准操作程序(SOP)。 建议的解决方案：根据瑞尔森大学联邦颁发的研究许可证，我们将开发从非精神活性药用植物品种的叶、茎和花组织中提取和分离萜类酚的SOP，以确定提取和鉴定这些化合物的可靠方法。

The Problem: First Access Medical plans to produce high-quality medicinal plant extracts to treat patients suffering from a variety of health issues, including pain, inflammation and tissue loss in arthritis. Plant-based prescriptions and even extracts from medicinal plant tissues contain a diversity of pharmaceutically relevant compounds including terpenophenols that must be extracted, isolated and identified for drug standardization, and to evaluate clinical applications. Significance of the Problem: Unless the constituent terpenophenols can be extracted, isolated, identified and evaluated at precise doses, attribution of medicinal activity to specific compounds in the treatment of particular diseases and the production of useful biopharmaceuticals will be difficult. Thus, there is an urgent need to establish standard operating procedures (SOP) for the extraction and isolation of terpenophenols compounds from plant tissues and extracts. Solutions Proposed: Working under a federally issued research license at Ryerson University, we will develop SOPs for the extraction and isolation of terpenophenols from the leaf, stem and floral tissues of a non-psychoactive, medicinal plant cultivars to determine a reliable method of extracting and identifying these compounds.